Skip to search formSkip to main contentSkip to account menu

Mylovenge

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma
Abstract 1958 Vaccines may offer additional benefit as consolidation therapy after plateau phase or autologous stem cell… 
Highly Cited
2009
Highly Cited
2009
Idiotype‐pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
Vaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We… 
2008
2008
Post Autologous Transplantation Consolidation of Multiple Myeloma with Idiotype-Pulsed Antigen Presenting (Dendritic) Cells (APC8020) Is Associated with Prolonged Survival.
Introduction: Immunotherapy is most likely to work in a setting of low tumor burden, making vaccine strategies attractive as… 
2002
2002
Technology evaluation: APC-80200, Dendreon.
  • Alison RiceD. Hart
  • Current opinion in molecular therapeutics (Print)
  • 2002
  • Corpus ID: 39529800
APC-80200 (Mylovenge) has been developed for the treatment of B-cell malignancies and is currently in phase II clinical trials as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)